AstraZeneca Partners with Abbisko on Lung Cancer Combination Trial

What happened

AstraZeneca signed a strategic collaboration agreement with Abbisko Therapeutics to advance a combination therapy trial for non-small cell lung cancer (NSCLC). The multicentre, open-label Phase I/II study will evaluate the safety and efficacy of combining Tagrisso (osimertinib), AstraZeneca's third-generation EGFR-TKI, with lumipodlin (ABSK043), Abbisko's investigational oral small-molecule PD-L1 inhibitor. The trial targets patients with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC. China's National Medical Products Administration (NMPA) cleared the investigational new drug (IND) application on 20 May 2026. Abbisko will lead the study, with both companies sharing clinical trial responsibilities.

Why it matters

This collaboration addresses an unmet medical need in lung cancer treatment. Patients with EGFR mutations and high PD-L1 expression typically derive less benefit from EGFR-TKIs alone, representing a significant treatment gap. The combination of an oral immunotherapy with Tagrisso could offer a differentiated therapeutic option for this patient population. For AstraZeneca, the partnership expands clinical exploration of Tagrisso, which has been prescribed to over one million patients globally, into novel combination strategies. Lumipodlin represents a first-in-class approach as an orally bioavailable PD-L1 inhibitor-currently no approved oral PD-1/PD-L1 drugs exist. Preclinical data suggest lumipodlin's anti-tumour activity is comparable to approved PD-L1 antibodies, potentially offering convenience advantages over intravenous therapies.

Bigger picture

The collaboration reflects broader industry efforts to develop combination therapies that target multiple cancer pathways simultaneously. Third-generation EGFR-TKIs like Tagrisso are the front-line standard of care for EGFR-mutated NSCLC, but resistance mechanisms and varying PD-L1 expression levels limit effectiveness in some patient subgroups. Combining targeted therapy with immunotherapy aims to improve outcomes by simultaneously blocking cancer growth pathways and enhancing immune system response. The focus on oral immunotherapy agents represents an emerging trend, as small-molecule drugs may offer dosing flexibility and patient convenience compared to injectable antibodies. For AstraZeneca's oncology franchise, this adds to ongoing efforts to broaden Tagrisso's clinical footprint across multiple NSCLC indications.

What to watch

Key upcoming signals include initial safety and tolerability data from the Phase I portion of the trial, followed by efficacy signals from the Phase II expansion. Investors should monitor enrollment progress in China and whether the combination demonstrates improved response rates compared to historical Tagrisso monotherapy data in this patient subset. Regulatory interactions beyond China-particularly whether the collaboration expands to other markets-will indicate the partnership's strategic scope. Additionally, watch for updates on lumipodlin's standalone Phase I study in Australia and China for advanced solid tumours, which may provide supportive safety and mechanism-of-action data. Competitive developments in oral immunotherapy and EGFR-TKI combinations will shape the commercial landscape.